Page 170 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux

2. MÉDICAMENTS DU DIABÈTE SUCRÉ UDUSABLES PAR VOIE ORALE 131

YAMAGISHI M., YAMADA Y., OZAKI K., ASAO M., SHIMIZU R., SUZUKI M., MATSU-
MOTO M., MATSUOKA Y. et MATSUMOTO K. Biological activities and quantitative
structure-activity relationships of spiro[imidazolidine-4,4'(1H)-quinazoline]-2,2',5
(3'H)-triones as aldose reductase inhibitors. J. Med. Chem., 1992, 35, 2085-2094.
Imirestat, Drugs of the Future, 1993, 18, 272-273.
Analogues ouverts
LIPINSKI C.A., ALDINGER C.E., BEYER T.A., BORDNER J., BURDI D.F., BUSSOLOTTI
P.B., INSKEEP P.B. et SIEGEL T.W., Hydantoin bioisosters. In vivo active spirohy-
droxy acetic aldose reductase inhibitors. J. Med. Chem. 1992, 35, 2169-2177.
Imides cycliques
MALAMAS M.S., SESTANJ K. et MILLEN J., Naphtalenylsulfonyl-hydantoins as aldose
reductase inhibitors. Eur. J. Med. Chem., 1991, 26, 369-374.
Airestatine, analogues et inhibiteurs irréversibles
ARES J.J., KADOR P.F. et MILLER D.D., Synthesis and biological évaluation of irréver­
sible inhibitors of aldose reductase. J. Med. Chem. 1986, 29, 2384-2389.
BUTERA J., BAGLI J., DOUBLEDAY W., HUMBER L., TREASUYWALA A., LOUGH-
NEY D., SETANJ K., MILLEN J. et SREDY J., Computer-assisted design and syn­
thesis of novel aldose reductase inhibitors. J. Med. Chem., 1989, 32, 757-765.
SMAR M.S., ARES J.J., NAKAYAMA T., ITABE H., KADOR P.F. et MILLER D.D.,
Sélective irréversible inhibitors of aldose reductase. J. Med. Chem.,1992, 35, 1117-
1120.
Toi restât
DOLLERY C. Tolrestat in : Dictionnary of drugs, Suppl, 206-210 CHURCHILL-
LIVINGSTONE, Edinburgh, 1992.
SESTANJ K., BELLINI F., FUNG S. ABRAHAM N., TREASURYWALA A., HUMBER L„
SIMARD-DUQUESNE N. et DVORNIK D., A/-[[5-trifluoromethyl]-6-methoxy-1-naph-
talenyl] thiomethyl]-A/-methylglycine (tolrestat), a potent, orally active aldose reduc­
tase inhibitor. J. Med. Chem., 1984, 27, 255-256.
ROBISON W.G., KADOR P.F., KINOSHITA J.H., GONZALEZ R. et DVORNIK D.,
Prévention of basement membrane thickening in retinal capillaries by a novel inhibi­
tor of aldose reductase, tolrestat. Diabètes, 1986, 35, 295-299.
LEE H.K. et QUERIJERO G., Kinetics and mechanisms of thioamide rotational isome-
rism : /V-thionaphthoyl-/V-methylglycine dérivative. J. Pharm. Sci., 1985, 74, 273-
276. Tolrestat (alredase) Drugs ofthe Future, 1986,11, 811-812 et 1989,14, 920.
MALAMAS M.S., SESTANJ K. et MILLEN J., Synthesis and biological évaluation of
tolrestat métabolites. Eur.J. Med. Chem., 1991, 26, 197-200.
GUIGLIANO D., MARFELLA R., QUATRARO A., DE ROSA N., SALVATORE T., COZ-
ZOLINO D., CERIELLO A. et TORELLA R., Tolrestat for mild diabetic neuropathy,
Annals of Internai Medicine, 1993, 118, 7-11.
Bioisostères du tolrestat
WROBEL J., MILLEN J., SREDY J., DIETRICH A., GORHAM B.J. et SESTANJ K.,
Orally active aldose reductase inhibitors derived from bioisosteric substitutions on
tolrestat. J. Med. Chem., 1989, 32, 2493-2500.